In conclusion, our study shows that selected BSG and SLC16A1 genetic variants may affect progression-free and overall survival in multiple myeloma, and correlate with various clinical parameters of MM, such as ISS stage, β-2-microglobulin and creatinine levels. The gene discussed is SLC16A1; the disease is plasma cell myeloma.